Member Login
|
Site Map
|
Disclaimer
|
Contact
|
Bookmark
Advanced Search
Text Size
|
Friday, September 10, 2010
Home
Home
>
Neura
>
Pharmacogenomic Analysis in Multiple Sclerosis
>
Lithium in Amyotrophic Lateral Sclerosis and Alzheimer’s Disease
>
References
References
1. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial ALS.
Nature
. 1993;362:59-62. [
PubMed
]
2. Bruijn LI, Miller Tm, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS.
Annu Rev Neurosci
. 2004;27:723-749. [
PubMed
]
3. Bruijn Li, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.
Science
. 1998;281:1851-1854. [
PubMed
]
4. Fornai F, Longone P, Ferrucci M, et al. Autophagy and ALS: the multiple roles of lithium.
Autophagy
. 2008;4:527-530. [
PubMed
]
5. Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase.
J Cell Biol
. 2005;170:1101-1111. [
PubMed
]
6. Fornai F, Longone P, Lenzi P, et al. Lithium delays progression of ALS.
Proc Natl Acad Sci USA
. 2008;105:2052-2057. [
PubMed
]
7. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Other Motor Neuron Disord
. 2000;1:293-299. [
PubMed
]
8. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis/motor neuron disease.
Cochrane Database Syst Rev
. 2007; 24:CD001447. [
PubMed
]
9. Meininger V, Shefner J, Cudkowicz M. Lithium therapy in ALS [commentary on reference 6].
Amyotroph Lat Scler
. 2008;9;122. [
PubMed
]
10. Fornai F, Siciliano G, Manca ML, et al. Lithium in ALS: from the bench to the bedside [commentary on reference 9].
Amyotroph Lat Scler
. 2008;9: 123-124. [
PubMed
]
11. Engel T, Goñi-Oliver P, Gómez de Barreda E, et al. Lithium, a potential protective drug in AD.
Neurodegener Dis
. 2008;5:247-249. [
PubMed
]
12. Klein PS, Melton DA. Molecular mechanism for the effect of lithium on development.
PNAS
. 2003;73;8455-8459. [
PubMed
]
13. Lovestone S, Davis DR, Webster MT, et al. Lithium reduces tau phosphorylation; effects in living cells and in neurons at therapeutic concentrations.
Biol Psychiatry
. 1999;45;995-1003. [
PubMed
]
14. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3b signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation.
J Neurosci
. 2007;27:1981-1991. [
PubMed
]
15. Rametti A, Esclaire F, Yardin C, et al. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Neurosci Lett.
2008;434;93-98. [
PubMed
]
16. Fulga TA, Elson-Schwab I, Khurana V, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.
Nat Cell Biol
. 2007;9:139-148. [
PubMed
]
17. Lindwall G, Cole RD. Phosphorylation affects ability of tau protein to promote microtubule assembly.
J Biol Chem
. 1984;259:5201-5305. [
PubMed
]
18. Tajes M, Gutierrez-Cuesta J, Folch J, et al. Lithium treatment decreases activities of tau kinases in a murine model of senescence.
J Neuropathol Exp Neurol
. 2008;67:612-623. [
PubMed
]
19. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for AD in elderly patients with bipolar disorder.
Br J Psychiatry
. 2007;190:359-360. [
PubMed
]
20. MacDonald A, Briggs K, Poppe M, et al. A feasibility and tolerability study of lithium in AD.
Int J Geriatr Psychiatry
. 2008;23:704-711. [
PubMed
]
21. Koh SH, Song, C, Noh MY, et al. Inhibition of GSK-3 reduces L-dopa-induced neurotoxicity.
Toxicology
. 2008;247:112-118. [
PubMed
]
22. Sarkar S, Krishna G, Imarisio S, et al. Rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin.
Hum Mol Genet
. 2008;17:170-178.[
PubMed
]
Neura.net is administered, managed, and populated by Expert Medical Education, a company dedicated to the education of healthcare professionals. The individual educational materials available here are supported by educational grants from Teva Neuroscience. This site is intended for U.S. audiences only. This Web site is for use by healthcare professionals only. It is not meant to serve as a substitute for a consultation with your physician. If you are a patient and would like to see Neura.net's educational material for patients,
click here
. Some discussions of drugs and devices contained on this Web site may include mention of uses that have not been evaluated by the United States Food and Drug Administration for safety and efficacy. Please consult complete prescribing information for any of the drugs and devices discussed before using them.
© 2010 Neura.net. All rights reserved.
